Jia Caiyun, Zhao Na, Song Haojing, Hu Yiting, Xu Yufang, Guo Caihui, Bai Wanjun, Dong Zhanjun
Department of Pharmacy and Hebei Key Laboratory of Clinical Pharmacy, Hebei General Hospital, No. 348 Heping West Road, Xinhua District, Shijiazhuang City, 050051, Hebei Province, People's Republic of China.
Drugs R D. 2024 Dec;24(4):531-538. doi: 10.1007/s40268-024-00493-3. Epub 2024 Oct 29.
Ondansetron is a highly selective 5-HT3 receptor antagonist that alleviates nausea and vomiting. Bioequivalence evaluation ensures that the efficacy of generic drugs is consistent with that of the original drug.
The objective of this study was to evaluate the bioequivalence of ondansetron hydrochloride (HCl) tablets taken in single doses under fasting and postprandial conditions in healthy subjects.
In this randomized, open-label, two-cycle, crossover phase I study, liquid chromatography‒tandem mass spectrometry (LC‒MS/MS) was used to determine the ondansetron concentration in dipotassium-ethylenediaminetetraacetate (K-EDTA) plasma after the subjects received a single 8 mg of ondansetron and reference formulation. Twenty-six healthy subjects received one tablet of ondansetron under fasting conditions and 28 subjects received one under postprandial conditions. Bioequivalence was established if the 90% confidence interval (CI) was 80.00-125.00%. The pharmacokinetic parameters were calculated via WinNonLin 8.1 software and the bioequivalence data were evaluated via Phoenix WinNonlin 8.1 statistics software.
The geometric mean ratio (GMR) of the maximum observed concentration (C), the area under the plasma concentration‒time curve (AUC) from time zero to the last sampling time (AUC), and the AUC from time zero to infinity (AUC) from the test/reference formulation under fasting conditions were 90.50, 90.43, and 90.25, respectively. The 90% CIs were 83.75-97.79, 82.64-98.95, and 82.25-99.03, respectively. The GMRs of C, AUC, and AUC after a high-fat meal were 96.85, 93.57, and 93.77, respectively; the 90% CIs were 88.43-106.07, 87.35-100.24, and 87.35-100.68, respectively.
The test and reference formulations of ondansetron HCl have bioequivalence for healthy adult subjects under fasting and postprandial conditions.
昂丹司琼是一种高度选择性的5-羟色胺3(5-HT3)受体拮抗剂,可缓解恶心和呕吐。生物等效性评估可确保仿制药的疗效与原研药一致。
本研究旨在评估健康受试者在空腹和餐后条件下单次服用盐酸昂丹司琼片的生物等效性。
在这项随机、开放标签、两周期、交叉的I期研究中,受试者接受单次8mg昂丹司琼和参比制剂后,采用液相色谱-串联质谱法(LC-MS/MS)测定乙二胺四乙酸二钾(K-EDTA)血浆中的昂丹司琼浓度。26名健康受试者在空腹条件下服用一片昂丹司琼,28名受试者在餐后条件下服用一片。如果90%置信区间(CI)为80.00%-125.00%,则判定具有生物等效性。通过WinNonLin 8.1软件计算药代动力学参数,并通过Phoenix WinNonlin 8.1统计软件评估生物等效性数据。
空腹条件下,受试制剂/参比制剂的最大观测浓度(Cmax)、血浆浓度-时间曲线下面积(AUC)从0时到最后一个采样时间(AUC0-t)以及从0时到无穷大时的AUC(AUC0-∞)的几何平均比值(GMR)分别为90.50、90.43和90.25。90%CI分别为83.75%-97.79%、82.64%-98.95%和82.25%-99.03%。高脂餐后Cmax、AUC0-t和AUC0-∞ 的GMR分别为96.85、93.57和93.77;90%CI分别为88.43%-106.07%、87.35%-100.24%和87.35%-100.68%。
盐酸昂丹司琼受试制剂与参比制剂在健康成年受试者空腹和餐后条件下具有生物等效性。